MVA-BN was approved by the European Medicines Agency (EMA) today for use against Mpox and smallpox in adolescents 12-17 years of age. This is of huge importance given the current Mpox outbreak has yet to be controlled and has disproportionately impacted children. Dr. Diemert and the GW VRU team are proud to have contributed critical clinical research needed to get this vaccine approved for this vital vulnerable population.
The Mpox Vaccine, MVA-BN, Receives Approval for Use in Adolescents 12 - 17 years of age
Latest News
The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This study showed promising results and can be read at the link below:
You are invited to attend the first featured presentation in the "State-of-the-Art Topics in Vaccinology" Seminar Series on Tuesday January 28, 2025 at 2 pm. by Dr. Nadine Rouphael, Executive Director of the Hope Clinic at the Emory Vaccine Center.
FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV